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ABSTRACT  
   
 The glycation of plasma proteins leading to the production of advanced glycation 
end products (AGEs) and subsequent damage is a driving factor in the pathophysiology 
of diabetic complications. The overall research objective was to elucidate the 
mechanisms by which birds prevent protein glycation in the presence of naturally high 
plasma glucose concentrations. This was accomplished through the specific purpose of 
examining the impact of temperature and glucose concentration on the percent glycation 
of chicken serum albumin (CSA) in comparison to human serum albumin (HSA). 
Purified CSA and HSA solutions prepared at four different glucose concentrations (0 
mM, 5.56 mM, 11.11 mM, and 22.22 mM) were incubated at three different temperatures 
(37.0°C, 39.8°C, and 41.4°C) on separate occasions for seven days with aliquots 
extracted on days 0, 3, and 7. Samples were analyzed by LC-ESI-MS for percent 
glycation of albumin. The statistically significant interaction between glucose 
concentration, temperature, albumin type, and time as determined by four-way repeated 
measures ANOVA (p = 0.032) indicated that all independent variables interacted to affect 
the mean percent glycation of albumin. As glucose concentration increased, the percent 
glycation of both HSA and CSA increased over time at all temperatures. In addition, 
HSA was glycated to a greater extent than CSA at the two higher glucose concentrations 
examined for all temperature conditions. Temperature differentially affected percent 
glycation of HSA and CSA wherein glycation increased with rising temperatures for 
HSA but not CSA. The results of this study suggest an inherent difference between the 
human and chicken albumin that contributes to the observed differences in glycation. 
Further research is needed to characterize this inherent difference in an effort to elucidate 
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the mechanism by which birds protect plasma proteins from glycation. Future related 
work has the potential to lead to the development of novel therapies to prevent or reverse 
protein glycation prior to the formation of AGEs in humans, thus preventing the 
development and devastating effects of numerous diabetic complications. 
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CHAPTER 1 
INTRODUCTION 
 Background. According to the most recent estimates, 29.1 million people in the 
United States, or 9.3% of the population, had diabetes in 2012 (Centers for Disease 
Control and Prevention, 2014). As the prevalence of diabetes continues to increase both 
in the U.S. and worldwide, so does the economic impact of this disease (Centers for 
Disease Control and Prevention, 2013). In the U.S. alone, $245 billion in direct and 
indirect costs were associated with diabetes in 2012 (American Diabetes Association, 
2013). More than 1 in 10 health care dollars in the U.S. are spent directly on diabetes and 
its complications (American Diabetes Association, 2013). The glycation of plasma 
proteins that leads to the production of advanced glycation end products (AGEs) and 
subsequent damage is a driving factor in the pathophysiology of diabetic complications 
such at retinopathy, nephropathy, and neuropathy (Brownlee, Vlassara, & Cerami, 1984). 
A clear understanding of the factors that affect the formation and destruction of AGEs is 
therefore essential for the prevention of these life-threatening complications. It is evident 
that both economic and health benefits would be seen worldwide from prevention of 
diabetic complications. 
 In order to further the understanding of diabetes, various animal species have 
been used as models of this disease. Avian species have proven a useful model because of 
something that my laboratory calls the “avian paradox”. Simply put, birds far outlive (by 
up to three times) mammals of comparable body size despite the fact that they exhibit 
certain biochemical parameters that would suggest the contrary (Braun & Sweazea, 2008; 
Holmes, Flückiger, & Austad, 2001; Speakman, 2005). The normal plasma glucose 
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concentrations of many species of birds are 1.5-2 times those of their mammalian 
counterparts of equivalent body mass (Braun & Sweazea, 2008). Interestingly, birds are 
also resistant to the glucose-lowering effects of insulin (Braun & Sweazea, 2008) and to 
protein glycation (Holmes et al., 2001). In fact, birds do not develop any complications 
that are associated with diabetes. These characteristics of birds suggest that the 
production of glycated proteins, not the elevated plasma glucose concentration, is what 
leads to further damage and promotes pathologies. Understanding the protective 
mechanisms by which birds avoid protein glycation despite high plasma glucose 
concentrations is crucial in the overall understanding of the avian paradox and the view 
of diabetes management in general. 
 Proposed theories to explain the lower levels of protein glycation in avian species 
are as follows: increased protein turnover (Jaensch, 2013), structural differences of 
plasma proteins (inability of glucose to bind to lysine on surface of protein because of 
physical obstruction or shielding due to differential protein folding), decreased 
abundance of proteins in the plasma (Bartholomew & Dawson, 1954), and the reactant-
favored chemical environment of bird plasma (higher plasma pH and body temperature 
relative to humans, which would reverse protein glycation) (Baumann & Baumann, 
1977). 
 Preliminary studies done in vitro have provided evidence to suggest that higher 
protein turnover rates as well as lower plasma protein concentration are not the factors 
responsible for decreased protein glycation in birds (Anthony, Sweazea & Braun, 2010). 
Specifically, it was shown that in vitro bovine albumin was more susceptible to protein 
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glycation than chicken albumin when matched molecule-for-molecule at species-specific 
physiologic conditions (Anthony et al., 2010). 
 Other preliminary work has shown that the percent glycated serum albumin 
measured using top down mass spectrometry was significantly lower in chicken plasma 
compared to samples obtained from healthy and type 2 diabetic humans (Borges, 
Unpublished). This finding supports the conclusion that plasma glucose cannot be used to 
accurately predict protein glycation in avian species. An intriguing theory, based on the 
reversible exothermic nature of the protein glycation reaction, predicts that the higher 
body temperature of birds in comparison to mammals may help to prevent protein 
glycation (Sweazea and Borges, Unpublished). Despite a potential correlation between 
the higher body temperatures of birds and protein glycation, no study has specifically 
looked at the reactant-favored chemical environment of bird plasma as a cause for the 
resistance to protein glycation in birds. Evidence to support the role of body temperature 
in the determination of percent protein glycation is needed in order to determine the 
validity of this proposed mechanism.  
 Validation of the reactant-favored chemical environment mechanism behind the 
decreased protein glycation in birds has the potential to lead to the development of novel 
therapies to prevent or reverse protein glycation prior to the formation of AGEs in 
humans. Thus, the detrimental effects of AGEs, such as the development of oxidative 
stress and inflammation that promote pathologies and further complications, could be 
avoided altogether (Brownlee et al., 1984). Therapies of this sort would be of particular 
interest to humans with diabetes as well as other hyperglycemic conditions as many of 
the long-term complications associated with these diseases stem from the detrimental 
!  4 
effects of elevated AGEs due to increased protein glycation caused by prolonged 
exposure to high plasma glucose concentrations. 
 Purpose of Study. The overall research objective was to elucidate the mechanisms 
by which birds prevent protein glycation in the presence of naturally high plasma glucose 
concentrations. This was accomplished through the specific purpose of this study that is 
to examine the impact of glucose concentration and temperature on the glycation of 
chicken serum albumin (CSA) in comparison to human serum albumin (HSA).  
 Research Aim and Hypotheses. The main research aim was to compare the impact 
of temperature and glucose concentration on percent glycated albumin of purified CSA 
and HSA samples over time. 
H0 1: The percent glycation of CSA will not significantly differ from the 
percent glycation of HSA when exposed to the same temperatures 
and glucose concentrations over seven days. 
H0 2: Variations in incubation temperatures will not differentially affect 
the percent glycation of CSA compared to the percent glycation of 
HSA incubated for seven days at the same glucose concentrations. 
H0 3: Variations in glucose concentrations will not differentially affect the 
percent glycation of CSA compared to the percent glycation of 
HSA incubated for seven days when the incubation temperature is 
constant. 
 Definition of Terms. The following is a list of terms and the author’s definition of 
each term that are commonly used throughout this thesis. 
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AGEs- Advanced Glycation End Products; compounds irreversibly 
formed in the body by the rearrangement and further modification 
of glycated proteins that are deleterious to many normal 
physiological processes 
CSA- chicken serum albumin 
GBM- glomerular basement membrane; the basal lamina layer of the 
glomeruli of the kidneys, which participates in the filtration 
function of the glomerulus 
GFR- glomerular filtration rate; an estimate of the amount of blood that 
passes through the glomeruli each minute and is used as a measure 
of kidney function (a lower GFR indicating poor renal function) 
Glycation- the non-enzymatic addition of sugars to proteins and nucleic 
acids 
HSA- human serum albumin 
In vitro- studies performed with biological cells or molecules outside of 
the normal biological context, i.e. in a test tube, flask, or petri dish 
 
 Delimitations and Limitations. Only purified, pooled CSA and HSA will be used 
in this experiment, thus the results may not be directly extrapolated to the whole animal 
or to other species, as there are inherent physiological differences between species. 
Limitations of this include the inability to account for variables such as age, nutrition 
status, and disease state of the chickens and humans from which serum albumin was 
collected for this study. Because of the inherent physiological differences between 
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mammals and birds, the findings from this study may not directly influence 
recommendations to the public, but may be used to guide further research and 
investigation. 
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CHAPTER 2 
REVIEW OF LITERATURE 
 Diabetes Mellitus. According to the Centers for Disease Control and Prevention, 
in 2012 there were 29.1 million people in the United States, or 9.3% of the population, 
living with diabetes (Centers for Disease Control and Prevention, 2014). Diabetes 
mellitus is reaching pandemic proportions and is currently the seventh leading cause of 
death in the United States. As the prevalence of diabetes continues to increase both in the 
U.S. and worldwide, so does the economic impact of this disease (Centers for Disease 
Control and Prevention, 2013). In the U.S. alone, $245 billion in direct and indirect costs 
were associated with diabetes in 2012 (American Diabetes Association, 2013). To put 
this in perspective, the direct spending alone on diabetes and its complications accounted 
for over 10% of all direct spending health care dollars in the U.S. (American Diabetes 
Association, 2013). 
 The pathophysiology of diabetes is dependent upon the type of diabetes with 
which an individual is diagnosed. There are two main types of diabetes mellitus, type 1 
and type 2. In adults, the most common form is type 2 diabetes (American Diabetes 
Association, 2014). Type 1 diabetes is much less prevalent in the U.S. population 
(American Diabetes Association, 2014). In addition, there are individuals that exhibit 
symptoms of diabetes during pregnancy (gestational diabetes) as well as a small number 
of individuals that have rare types of diabetes caused by genetic conditions or other 
environmental factors such as surgery, pancreatic injury/disease, medications, or other 
diseases (American Diabetes Association, 2014).  The major differences between type 1 
and type 2 diabetes are outlined in Table 1. 
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Diabetes diagnosis is based on the positive results of one of three tests: fasting 
plasma glucose (FPG) greater than 125 mg/dL, hemoglobin A1C greater than 6.5%, or a 
oral glucose tolerance test (OGTT) indicating a two hour blood glucose concentration 
greater than 199 mg/dL as presented in Table 2 (American Diabetes Association, 2014). 
A positive result for diabetes from any of the three tests must be obtained on a second 
occasion in order to confirm the diagnosis.  
 
Table 2. Criteria for classification as normal, prediabetes, or diabetes based on 
results of A1C test, Fasting Plasma Glucose (FPG) test, or Oral Glucose Tolerance 
Test (OGTT) 
Test Normal Prediabetes Diabetes 
A1C, % <5.7 5.7-6.4 ≥6.5 
Fasting Plasma Glucose, mg/dl <100 100-125 ≥126 
Oral Glucose Tolerance Test, mg/dl <140 140-199 ≥200 
    (American Diabetes Association, 2014) 
Table 1. Major Differences between Type 1 and Type 2 Diabetes 
  Type 1 Type 2 
Pathophysiology Autoimmune destruction of 
pancreatic beta cells 
resulting in little to no 
insulin production 
Insulin resistance; inability of 
pancreatic beta cells to 
produce sufficient insulin; or 
other cause 
Endogenous Insulin Low or absent Present (can be increased or 
decreased) 
Onset Sudden Gradual 
Age at Onset Usually Childhood or Early 
Adulthood 
Generally later in life 
(adulthood); can occur in 
childhood 
Nutritional Status at 
onset 
Commonly undernourished Obesity frequently present 
Prevalence in 
general population 
about 5-10% of diagnosed 
diabetics 
about 90-95% of diagnosed 
diabetics 
    (American Diabetes Association, 2014) 
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 No matter the type of diabetes, the hallmark of the disease is the presence of high 
blood glucose concentrations caused by the lack of insulin production, the inability of 
insulin to function properly (known as insulin resistance), or a combination of both of 
these conditions (American Diabetes Association, 2014). Insulin is a regulatory hormone 
produced by the beta-cells of the pancreas (Saltiel & Kahn, 2001). One of the primary 
functions of insulin in the body is the regulation of glucose transport via insulin-mediated 
glucose uptake into adipose tissue, skeletal muscle, and cardiac muscle where it functions 
to increase glucose uptake (Saltiel & Kahn, 2001). The mechanism of action of insulin-
mediated glucose uptake begins with the binding of insulin to the insulin receptor on the 
surface of the cell (Huang & Czech, 2007; Saltiel & Kahn, 2001). This triggers a cascade 
of intracellular signaling that leads to the translocation of the glucose transporter isoform 
4 (GLUT4) from intracellular vesicles to the surface of the cell (Shepherd & Kahn, 
1999). Once at the surface of the cell membrane, GLUT4 is able to transport glucose into 
the cell. Acute exercise can also stimulate the translocation of GLUT4 to the cell 
membrane, albeit, through a different signaling pathway than insulin (Shepherd & Kahn, 
1999; Huang & Czech, 2007; Saltiel & Kahn, 2001). GLUT4 is a key determinant of 
glucose homeostasis, thus decreased expression or translocation of GLUT4 will have a 
significant affect on blood glucose (Huang & Czech, 2007). The absence of insulin 
production makes the insulin-mediated translocation of GLUT4 impossible, resulting in 
severe imbalance in glucose homeostasis (i.e. type 1 diabetes). Insulin resistance is the 
diminished ability of insulin to trigger the translocation of GLUT4 to the cell membrane 
surface (Reaven, 1995). Insulin resistance disrupts glucose homeostasis resulting in 
improperly regulated blood glucose concentrations and inefficient nutrient utilization 
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(Reaven, 1995; Shepherd & Kahn, 1999). The exact cause of insulin resistance is 
currently being studied. Research indicates that excess weight and physical inactivity are 
associated with insulin resistance (Reaven, 1995). Also, there are studies that show fat 
can directly induce insulin resistance by inhibiting the insulin signaling pathway 
intermediates (Turinsky, O’Sullivan, & Bayly, 1990). 
 Insulin also serves an important role in the facilitation of metabolic processes in 
the liver. For example, insulin acts through intracellular signaling within the liver to 
stimulate glycogen synthesis and cell growth/division, inhibit gluconeogenesis and 
ketone body production as well as modify lipoprotein metabolism and protein synthesis 
(Denton & Tavare, 1997). Insulin deficiency consistently opposes these metabolic 
processes; however, insulin resistance differentially affects these metabolic processes 
(Wilcox, 2005). Specifically, insulin resistance in the liver further promotes 
hyperglycemia via increased gluconeogenesis and alters lipoprotein metabolism as in 
insulin deficiency; however, hyperinsulinaemia present in insulin resistance also further 
promotes the mitogenic effects of insulin (Denton & Tavare, 1997; Wilcox, 2005).
 Of those currently living with diabetes in the U.S., nearly 28% are undiagnosed 
(Centers for Disease Control and Prevention, 2014). These individuals are not receiving 
the medical attention necessary to properly treat and manage their disease in order to 
prevent further complications. When properly managed, individuals with diabetes can 
live a long, healthy life after diagnosis devoid of the acute complications of the disease. 
Nonetheless, even patients with very well-controlled diabetes are likely to develop 
chronic diabetic complications.  
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 Diabetic Complications. Many of the complications associated with diabetes pose 
a serious risk to health (Zhou et al., 2005). Complications are both acute as well as 
chronic and include conditions such as diabetic ketoacidosis (DKA), hyperosmolar 
hyperglycemic nonketotic syndrome (HHNS), gastroparesis, hypoglycemia, 
hyperglycemia, skin complications, retinopathy, neuropathy, nephropathy, hypertension, 
stroke, heart disease, and mental health problems (American Diabetes Association, 2014; 
Pirart, 1977). Research has shown that hyperglycemia as a result of insulin resistance or 
insulin insufficiency is the driving factor responsible for the development of many of 
these chronic diabetic complications (Pirart, 1977). Using intensive diabetes management 
to control blood glucose levels has been shown to delay the onset of diabetic 
complications; however, it is associated with an increased risk for hypoglycemia 
(Fullerton et al., 2014). The aim of intensive control of blood glucose is to keep blood 
glucose levels within a normal range for the majority of the time throughout the day. 
Generally, this results in a lower average glucose concentration in the blood over time. 
Less glucose available to interact with proteins in the blood means that there is less 
opportunity for protein glycation to occur, which results in decreased production of 
advanced glycation end products (AGEs) (Khan, Rasheed, Khan, & Ali, 2007). A high 
level of plasma protein glycation and subsequent production of AGEs due to prolonged 
exposure to high blood glucose levels in individuals with diabetes is one of the primary 
mechanisms responsible for the development of many diabetic complications (Brownlee 
et al., 1984; Khan et al., 2007). 
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Non-Enzymatic Protein Glycation and AGEs. Protein glycation is the non-
enzymatic addition of a reducing sugar (i.e. glucose) to an amino acid residue (usually 
lysine) of a protein resulting in the formation of a Schiff base. The formation of a Schiff 
base is highly reversible, thus the reaction can be driven backwards (Brownlee et al., 
1984; Ulrich & Cerami, 2001). Numerous plasma proteins are subject to protein 
glycation. Albumin, hemoglobin, and collagen are just a few examples of these plasma 
proteins with important physiologic functions that are subject to protein glycation in 
mammals (see Table 3 for additional examples). The Schiff base that forms during the 
Table 3. Partial List of Human Plasma Proteins with Important Physiologic Functions 
that are Subject to Protein Glycation 
Protein 
Albumin 
Antithrombin III 
Beta-NAc-D-glucosaminidase 
Cathepsin B 
Collagen 
Coronary artery proteins 
Endothelial cell membrane 
Ferritin 
Fibrin 
Fibrinogen 
Glomerular basement membrane 
Hemoglobin 
High density lipoproteins 
Lens capsule 
Lens crystallins 
Low density lipoproteins 
Myelin 
Pancreatic RNase 
Red cell membrane 
Tubulin 
 
    Table 3 adapted from Brownlee et al., (1984). 
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initial glycation reaction can undergo further rearrangement to form an Amadori Product, 
a stable sugar-protein adduct (Brownlee et al., 1984; Ulrich et al, 2001). This 
rearrangement is also chemically reversible. The accumulation of Amadori products from 
proteins with a slow turnover rate leads to the development of post-Amadori non-
enzymatic glycation products through additional rearrangements and dehydration 
reactions, which are known as advanced glycation end products (AGEs) (Brownlee et al., 
1984; Ulrich et al, 2001). While the rate of formation of AGEs is much slower than that 
of Schiff bases or Amadori products, the formation of AGEs is irreversible thus these 
products continue to accumulate once formed (Brownlee et al., 1984). A simplified 
diagram of the formation of AGEs is illustrated in Figure 1.  
 
 
 
 
 
Figure 1. The Formation of Advanced Glycation End Products (AGEs). Adapted from 
(Tarr, Kaul, Chopra, Kohner, & Chibber, 2013). 
 
The glycation of plasma proteins has many physiological effects. This structural 
change to the protein can alter its function and thus alter any processes in which the 
protein is involved (Khan et al., 2007). For example, protein glycation can alter 
enzymatic activity, binding of regulatory molecules, cross-linking of proteins, 
Glucose!
Protein!
+! Schiff!Base! Amadori!!Product! AGE!Days!Hours! Weeks/!Months!
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susceptibility to proteolysis, function of nucleic acids, macromolecular recognition and 
endocytosis, and immunogenicity (Khan et al., 2007). The inability of the glycated 
protein to perform its physiological function and the new ability of the glycated protein to 
cause damage to surrounding tissues leads to the development of many diabetic 
complications (Singh, Bali, Singh & Jaggi, 2014). 
 Albumin as a Measure of Overall Protein Glycation. All plasma proteins in the 
body are susceptible to protein glycation. The extent to which different plasma proteins 
are glycated varies significantly from one protein to another as well as between 
euglycemic and hyperglycemic states (Austin, Mullins, & Morin, 1987). The differences 
in the extent of glycation between proteins can mostly be attributed to variations in half-
life and glycation susceptibility of the different proteins (Austin et al., 1987). Albumin is 
the most abundant plasma protein. It is freely circulating, has a relatively long half-life, 
and has numerous physiological functions in addition to serving as an antioxidant (Kim 
& Lee, 2012; Singh et al., 2014). Compared to other plasma proteins, albumin exhibits a 
relatively high proportion of glycation when exposed to the same glycemic conditions for 
the same length of time (Austin et al., 1987). This characteristic justifies the use of 
albumin as a marker of overall protein glycation as it will accurately reflect the maximum 
proportion of overall glycation in a relatively short amount of time. In addition, previous 
work has shown that the susceptibility of albumin to glycation does not greatly differ 
across mammalian species as it does for other plasma proteins (i.e. hemoglobin) (Rendell 
et al., 1985). 
 Clinically, the measurement of glycated albumin has been used to assess blood 
glucose control. The use of glycated albumin in place of hemoglobin A1C as a measure 
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of protein glycation in order to assess blood glucose control has grown in clinical utility 
(Kim & Lee, 2012). Albumin has a half-life of 12 to 21 days (Rondeau & Bourdon, 
2011). This is significantly shorter than the half-life of hemoglobin, which is the plasma 
protein currently considered the ‘gold standard’ for assessing protein glycation (Kim & 
Lee, 2012). Studies have found a strong correlation between the glycation of albumin 
over a 3-week period and the glycation of hemoglobin over a 3-month period (Kim & 
Lee, 2012). Therefore, the use of albumin as a marker of protein glycation allows an 
assessment of blood glucose control over a shorter-period of time (Rondeau & Bourdon, 
2011; Kim & Lee, 2012). 
 Quantification Methods for Determination of Protein Glycation. Methods to 
accurately quantify the extent of protein glycation within a specific sample are critical 
when using this measure in research as well as in the clinical setting. The increasing 
evidence and knowledge regarding the influence that glycated proteins have on biological 
processes has driven the development of techniques to detect protein glycation with 
greater sensitivity and higher throughput (Lee et al., 2011; Lapolla, Molin, & Traldi, 
2013). Numerous methods to determine the degree of protein glycation present in a 
particular sample have been described and previously utilized.  
 The two main approaches to measuring protein glycation are the binding methods 
and the chemical methods (Schleicher & Wieland, 1989). The binding methods involve 
the binding of a reagent to the glycated protein. Binding methods are equilibrium 
reactions and do not chemically alter the glycated protein. Thus, the glycated protein will 
remain unchanged if the reagent is removed (Schleicher & Wieland, 1989). Chemical 
methods, on the other hand, result in modification of the glycated protein. This 
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modification is dependent upon the specific chemical methods used, however, it usually 
involves hydrolysis or oxidation of the glycated protein (Schleicher & Wieland, 1989).  
 The exact method of analysis used is determined by the level of detail required in 
the analysis. Simply detecting the presence of protein glycation is the first step in any 
analysis and is generally accomplished by either glycan staining/labeling or affinity-
based methods (Roth, 2012). The most common staining procedures utilize sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to separate the proteins 
based on charge and then stain the gel for glycated proteins (Roth, 2012). The gel is 
stained using the periodic acid-Schiff (PAS) reaction that results in a magenta color that 
can be quantified when the aldehyde is formed (Roth, 2012). Affinity-based methods can 
be enzyme-based or antibody-based and tend to be more specific than staining by 
allowing the determination of the type of glycation present (Roth, 2012). Once protein 
glycation has been detected, the exact structure of the glycan, type of glycation and the 
extent of glycation can be analyzed using more sophisticated techniques (Roth, 2012). 
Chromatography and mass spectrometry are commonly used for this type of protein 
glycation analysis. The analysis can be conducted on the glycated protein or after 
glycoprotein purification (Roth, 2012). Recently, the combined use of liquid 
chromatography (LC) and mass spectrometry (MS), known as LC-MS has been utilized 
in the analysis of protein glycation (Borges et al., 2011). The development of this 
technique has allowed for higher throughput and greater sensitivity in analyses (Wuhrer, 
Deelder, & Hokke, 2005). In addition, this method has the ability to pinpoint and quantify 
individual albumin molecules with two (i.e. doubly-glycated), rather than just one, 
glucose molecules attached. This level of precision in measurement allows for a more 
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thorough and detailed examination of the extent of protein glycation in a sample that is 
not available using other methods (Wuhrer et al., 2005).  
 Overall, there are numerous methods available for measuring and quantifying 
protein glycation. The technique chosen should be selected based upon the level of 
analysis required. The level of analysis required will vary based upon the use of data. 
Research purposes generally require much more detailed analyses in order to properly 
answer the research question, thus more sophisticated techniques such as LC-MS should 
be considered. Clinical purposes typically are more time-sensitive and only require the 
identification of the level of glycation present!not a complete structure analysis, thus 
assays and staining methods are preferable. 
 The Role of AGEs in the Development of Diabetic Complications. The mechanism 
by which AGEs promote the development of diabetic complications is unique to each 
complication. Generally, AGEs cause damage throughout the body by interacting with 
specific receptors located on the membrane of numerous cells called receptors for 
advanced glycation end products (RAGEs) (Ramasamy, Yan, & Schmidt, 2011; 
Szwergold & Miller, 2014; Singh, 2014). When the activation of RAGEs is exacerbated, 
there is increased deposition of AGEs in tissues and the oxidative stress response that is 
triggered is amplified (Ramasamy et al., 2011; Szwergold & Miller, 2014; Singh 2014). 
The specific role of AGEs has been classified for the development of the following 
microvascular and macrovascular diabetic complications: neuropathy, nephropathy, 
retinopathy, and macrovascular disease. 
 Neuropathy in diabetic patients is usually in the form of peripheral neuropathy 
and presents as numbness or paralysis of the extremities (Brownlee & Cerami, 1981). 
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Diabetic peripheral neuropathy is the leading cause of non-emergency amputations in the 
U.S. There is evidence to support the role of AGEs in the development of peripheral 
neuropathy (Sugimoto, Yasujima, & Yagihashi, 2008). Several structural proteins of 
nerve, vessel, and extracellular matrix cells of peripheral nerves that have been modified 
by AGEs have been identified in humans (Wada & Yagihashi, 2005). This interaction of 
AGEs with structural proteins leaves the peripheral nerve cells susceptible to 
degeneration (Sugimoto et al., 2008). Specifically, these interactions take many forms 
depending on the protein involved. For example, segmental demyelination of peripheral 
nerves can be caused by increased phagocytosis of AGE-modified peripheral nerve 
myelin; AGE interaction with tubulin, neurofilament, and actin of the axon leads to 
axonal atrophy and impaired axonal transport; and modification of laminin by AGEs 
impairs cell regeneration activity (Sugimoto et al., 2008). 
 Another diabetic complication in which the AGE mechanism is proposed to 
contribute is nephropathy. This type of renal disease usually seen in long-term diabetic 
patients is characterized by proteinuria and decreased glomerular filtration rate (GFR). 
Increased presence of glycated proteins has been linked to the thickening of the 
glomerular basement membrane (GBM), which is positively correlated with severity of 
symptoms (Brownlee & Cerami, 1981; McVerry, Fisher, Hopp, & Huehns, 1980). It is 
the progressive thickening of the GBM that alters the filtering ability of the glomerulus, 
causes capillary occlusion, and eventually leads to renal failure (Brownlee & Cerami, 
1981). Thus, glycated proteins have been implicated as a driving factor in the 
development of nephropathy in individuals with diabetes.  
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 The increased production of AGEs in individuals with diabetes increases their 
likelihood to develop retinopathy. Diabetic retinopathy is the leading cause of blindness 
in adults aged 20 to 74 years (Tarr et al., 2013). It has been shown in experimental trials 
that increased accumulation of AGEs was accompanied by loss of pericytes, formation of 
microaneurysms, and formation of acellular capillaries that contribute to retinal damage 
(Hammes, Martin, Federlin, Geisen, & Brownlee, 1991; Stitt et al., 2002). In addition, 
research has found a direct correlation with the quantity of AGEs measured in patients   
and the presence/severity of diabetic retinopathy (McCance et al., 1993). 
 Diabetes has been shown to be an independent risk factor for certain 
macrovascular complications including atherosclerosis, cardiovascular disease, 
cerebrovascular disease, and peripheral artery disease (Cade, 2008). Higher AGE levels 
in diabetic patients have been correlated with adverse atherosclerotic lipid profiles 
suggesting a possible role for AGEs in the development of these lesions/plaques and the 
use of AGE levels as an indicator of atherosclerosis risk (Chang, Chu, Syu, Hsieh, & 
Hung, 2011). The development of macrovascular complications in individuals is a 
multifactorial process. Studies have shown that one factor in this process is the ability of 
AGEs to quench nitric oxide (NO) as well as inhibit NO production leading to an 
impaired vasodilatory response (Cade, 2008; Linden et al., 2008). In addition, AGEs 
promote the accelerated development of atherosclerosis through collagen cross-linking, 
increased susceptibility of LDL to oxidation, and several other identified mechanisms 
(Basta, Schmidt, & De Caterina, 2004). 
 The glycation of plasma proteins that leads to the production of AGEs and 
subsequent damage is a driving factor in the pathophysiology of the diabetic 
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complications of retinopathy, nephropathy, neuropathy and macrovascular disease 
(Brownlee et al., 1984). A clear understanding of the factors that affect the formation and 
destruction of AGEs is essential for the prevention of these life-threatening 
complications. It is evident that both economic and health benefits would be seen 
worldwide from prevention of diabetic complications. 
 Current Therapies to Reduce AGEs. In the clinical setting, current therapies for 
treating patients with high levels of protein glycation typically focus on lowering blood 
glucose levels to provide less substrate for glycation or focus on reducing the side effects 
of glycated proteins as they promote inflammation and oxidative stress (Fullerton et al., 
2014). Strictly monitoring blood glucose levels is an effective method to decrease protein 
glycation thus reducing AGE formation; however, it requires strict adherence and a high 
level of cooperation from the patient. In addition, it significantly increases the risk of 
hypoglycemic events (Fullerton et al., 2014). Therapies that focus on reducing the side 
effects of glycated proteins and AGEs can effectively delay the onset of complications 
and treat the symptoms, yet they do not address the underlying problem. There is a clear 
gap in our understanding of protein glycation that leads to the inadequacy of our current 
therapies. A better understanding of what makes proteins susceptible to glycation has the 
potential to lead to alternative therapies for decreasing the rate of protein glycation. 
 Birds as a Model of Type 2 Diabetes. In order to further understand the 
pathogenesis of diabetic complications, various animal species have been used as models 
of this disease. Traditional animal models, such as rats and mice, have little promise in 
the further study of diabetic complications (Szwergold & Miller, 2014). These animals 
typically do not live long enough to develop the complications seen in humans and the 
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inherent differences in the biochemistry and physiology of the species make any findings 
difficult to extrapolate to humans (Szwergold & Miller, 2014). Recently, interest has 
been placed on the use of birds as a model of type 2 diabetes for several reasons (Braun 
& Sweazea, 2008; Iqbal, Probert, Alhumadi, & Klandorf, 1999; Klandorf, Rathore, Iqbal, 
Shi, & Van Dyke, 2001; Szwergold & Miller, 2014). Despite having 1.5-2 times the 
blood glucose concentrations as a mammal of comparable body mass (Braun & Sweazea, 
2008), birds do not exhibit symptoms of diabetes nor develop diabetic complications, 
which counterintuitively makes them a useful model to study. The interspecies 
differences between humans and other animal models (rats, mice, etc.) hinder 
investigation by complicating extrapolation of findings; however, the interspecies 
differences are in fact an asset in the bird model. The goal of research using bird models 
is to obtain understanding of these differences in order to apply them to humans. 
 Currently, only a handful of researchers in the United States use birds as a 
pathology-free model of type 2 diabetes (Braun & Sweazea, 2008; Iqbal, Probert, 
Alhumadi, & Klandorf, 1999; Klandorf, Rathore, Iqbal, Shi, & Van Dyke, 2001; 
Szwergold & Miller, 2014). This research has led to the discovery of several 
physiological differences between humans and birds that aid in the understanding of 
avian blood glucose regulation. Of particular interest is the lack of evidence to support 
the presence of the gene encoding for RAGEs in birds and therefore the presence of 
RAGEs altogether (As reviewed in: Szwergold & Miller, 2014). The lack of RAGEs in 
birds could explain why birds with high blood glucose concentrations do not develop the 
same complications that humans would develop at comparable blood glucose 
concentrations. Nonetheless, the lack of the RAGE gene and RAGE proteins in birds 
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does not adequately explain the mechanism by which birds’ plasma proteins are protected 
from protein glycation and have a relatively lower production of AGEs in comparison to 
humans. 
 Another reason that avian species have proven a useful model of pathology-free 
type 2 diabetes is because of something the laboratory of the author’s mentor has termed 
the “avian paradox”. Simply put, birds far outlive (by up to three times) mammals of 
comparable body size despite the fact that they exhibit certain biochemical parameters 
that would suggest the contrary (Braun & Sweazea, 2008; Holmes et al., 2001; 
Speakman, 2005). In particular, the higher metabolic rates, higher body temperatures, and 
higher blood glucose levels that are observed in many avian species should predispose 
them to more rapid aging according to the current biochemical model of aging in 
mammals (Speakman, 2005). This is due to the increased production of harmful by-
products, such as reactive oxygen species (ROS) and AGEs, caused by these biochemical 
conditions; however, this is not the case for birds (Holmes et al., 2001). As previously 
mentioned, the normal plasma glucose concentrations of many species of birds are 1.5-2 
times those of their mammalian counterparts of equivalent body mass (Braun & Sweazea, 
2008). Fasting plasma glucose concentration in humans is normally 80-100 mg/dL. 
Humans will begin to experience symptoms of diabetes when fasting plasma glucose 
concentrations are around 126 mg/dL for an extended period of time. For birds, plasma 
glucose concentrations are normally at a level that would be considered hyperglycemic 
for humans (Baumann & Baumann, 1977; Beuchat & Chong, 1998; Braun & Sweazea, 
2008). This relationship between plasma glucose concentration and body mass is depicted 
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in Figure 2 and illustrates the comparatively higher plasma glucose concentrations of 
birds (Baumann & Baumann, 1977; Beuchat & Chong, 1998; Braun & Sweazea, 2008). 
Figure 2. The relationship between plasma glucose concentrations and log body mass 
(LBM in kg) for birds (n=97) and mammals (n=162). Data were extracted from the 
International Species Information System (ISIS), Physiological Data Reference Values 
2002. Adapted from Braun & Sweazea, 2008. 
 
Interestingly, birds are also resistant to the glucose-lowering effects of insulin 
(Braun & Sweazea, 2008; Sweazea & Braun 2005; Sweazea, McMurtry & Braun 2006).  
The GLUT4 transport protein responsible for insulin-mediated uptake of glucose into 
cells is not present in the skeletal muscle cells of several avian species that have been 
examined. This lack of GLUT4 transporters in the muscle cells causes a different insulin 
response in avian species compared to humans. In fact, a very high dose of insulin is 
required to cause a significant drop in blood glucose concentration in these avian species 
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(Carver, 2001; Seki, 2003; Sweazea, 2005; Sweazea, 2006a; Sweazea, 2006b). Also, 
protein glycation has been shown to occur at a significantly lesser degree in several avian 
species despite higher blood glucose concentrations (Review: Holmes et al., 2001). A 
study examining hemoglobin glycation found these plasma proteins to be in the range of 
0.5-1.0% glycation in three avian species (duck, chicken, and turkey), while mammals 
fell in the range of 1.7-5.8% glycation (Beuchat, 1998). Hummingbirds, which are known 
to have among the highest fasting plasma glucose concentrations of all measured 
vertebrates (roughly 300-756mg/dl in the fasted and fed states, respectively), were found 
to have glycated hemoglobin levels in the range of 3.7-4.6% glycation. While higher than 
other avian species, the percent glycation is still significantly lower than observed in 
diabetic humans (Beuchat & Chong, 1998). Additionally, a lower degree of plasma 
albumin glycation was observed in budgerigars (parakeets) in comparison to human 
plasma albumin (Holmes et al., 2001). 
 The observed protection from protein glycation seen in birds suggests a possible 
mechanism by which birds are able to maintain high plasma glucose concentrations 
without detrimental effects that would result in humans at comparable levels. This 
characteristic of birds also suggests that it is the production of glycated proteins, not the 
elevated plasma glucose concentration, which leads to further damage and promotes 
pathologies. While these studies clearly present the disparity in the level of protein 
glycation, they do not address specifically how birds are able to protect circulating 
proteins from glycation at high plasma glucose concentrations. Understanding the 
protective mechanisms by which birds avoid protein glycation despite high plasma 
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glucose concentrations is crucial in the overall understanding of the avian paradox and 
the progress towards improved diabetes management in general. 
 Proposed Mechanisms for Low Protein Glycation in Birds. Proposed theories to 
explain the lower levels of protein glycation in avian species are as follows: increased 
protein turnover (Jaensch, 2013), structural differences of plasma proteins (inability of 
glucose to bind to lysine on surface of protein because of physical obstruction/shield due 
to differential protein folding- Sweazea unpublished), decreased abundance of proteins in 
the plasma (Bartholomew & Dawson, 1954), and the reactant-favored chemical 
environment of bird plasma (higher plasma pH and body temperature relative to humans) 
(Baumann & Baumann, 1977). 
 Preliminary studies done in vitro have provided evidence to suggest that higher 
protein turnover rates as well as lower plasma protein concentration are not the factors 
responsible for decreased protein glycation in birds (Anthony et al., 2010). Specifically, it 
was shown that in vitro bovine albumin was more susceptible to protein glycation than 
chicken albumin when matched molecule-for-molecule at species-specific physiologic 
conditions (Anthony et al., 2010). The study was conducted in vitro, negating the theory 
of increased protein turnover as the driving mechanism, and albumin molecules were 
matched molecule-for-molecule, negating the theory of decreased abundance of proteins 
in the plasma. 
 Other preliminary work has shown that the percentage of glycated serum albumin 
measured using top down mass spectrometry was significantly lower in chicken plasma 
compared to samples obtained from healthy and type 2 diabetic humans (Sweazea and 
Borges, unpublished). This finding supports the conclusion that plasma glucose cannot be 
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used to accurately predict protein glycation across species. Even within avian species, 
plasma glucose cannot accurately be used to predict protein glycation. Based on the 
exothermic nature of protein glycation, it is reasonable to predict that the higher body 
temperatures of birds may be a factor that protects them from protein glycation (Sweazea 
and Borges, unpublished). Despite this suggested correlation, no study has specifically 
looked at the reactant-favored chemical environment of bird plasma as the cause for the 
lower level of protein glycation in birds. Further evidence to support the role of 
temperature in the determination of percent protein glycation is needed in order to 
determine the validity of this proposed mechanism.  
 Validation of the reactant-favored chemical environment mechanism behind the 
decreased protein glycation in birds has the potential to lead to the development of 
therapies to prevent or reverse protein glycation prior to the formation of AGEs in 
humans. Thus, the detrimental effects of AGEs, such as the development of oxidative 
stress and inflammation that promote pathologies and further complications, could be 
avoided altogether (Brownlee et al., 1984). Therapies of this sort would be of particular 
interest to humans with diabetes as well as other hyperglycemic conditions as many of 
the long-term complications associated with these diseases stem from the detrimental 
effects of elevated AGEs due to increased protein glycation caused by prolonged 
exposure to high plasma glucose concentrations. 
 Role of Temperature in Chemical Reactions. The chemical environment in which 
a reaction is taking place significantly impacts the rate at which the chemical reaction 
proceeds. Regulation of biochemical reactions is complex and is impacted by many 
factors. One factor influencing the chemical environment is temperature. In general 
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chemistry, as the temperature of the chemical environment is increased the rate of the 
reaction will increase due to the collision theory. The reverse, namely a decrease in 
temperature results in a decrease in the rate of the reaction, is also generally true. This 
relationship is not as simple in biochemical reactions. In physiological conditions, 
enzymes catalyze the majority of biochemical reactions. High temperatures (i.e during a 
fever) can cause enzymes to denature, thus destroying their ability to function 
catalytically. Thus, in biochemical conditions an ideal temperature is strictly regulated 
and maintained to ensure that all biological reactions occur at the desired rate. In 
physiological conditions, the body temperature is considered the temperature of the 
chemical environment. 
 Human and Avian Body Temperature. Humans and birds both tightly regulate 
internal body temperature through thermoregulation processes. Most animals are not 
capable of thermoregulation, thus birds and mammals are among the minority of animals 
capable of effectively controlling internal body temperature (Whittow, 1999). While the 
thermoregulatory processes serve a similar purpose among birds and mammals, there are 
differences in the specific mechanisms and behaviors utilized to achieve the temperature 
stabilization (Whittow, 1999). 
 Normal human body temperature is considered to be around 37.0°C (Sherwood, 
2008). Evidence that the normal body temperature for healthy humans is actually a range 
of temperatures from 35.5°C to 37.7°C suggests that temperatures of healthy humans can 
vary from one individual to another (Sherwood, 2008). There are several factors that 
influence body temperature including age, gender, genetics, disease/infection status, and 
activity and temperature is known to fluctuate slightly throughout the day (Sherwood, 
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2008).  In addition, some foods and food components such as vitamin C, spices, teas, and 
caffeine have been shown to elicit changes in metabolism that impact thermogenesis 
(Johnston, 1990; Johnston, 1989; Westerterp-Plantenga, Diepvens, Joosen, Berube-
Parent, & Tremblay, 2006).  
 Birds have normal body temperatures in the range of 35°C to 43°C dependent 
upon the species (see Table 4) (Whittow, 1999). Typically, normal body temperatures of 
birds are around 39-42°C (Whittow, 1999). Therefore, on average, birds have higher 
normal body temperatures than mammals, such as humans. In addition to having higher 
normal body temperatures than humans, the body temperature of some avian species can  
experience greater daily fluctuations than the average human. The body temperature of 
some smaller avian species (i.e. hummingbirds) can vary by up to 8°C in a single day, 
while larger birds typically do not fluctuate more than 1°C in a single day (Whittow, 
1999).  This difference in the amplitude of the normal circadian rhythm of body 
temperature is likely due to the fact that, as previously mentioned, thermoregulation of 
Table 4. Body Temperatures of Selected Birds at Rest  
Species Body Temperature (°C ) 
Domestic turkey (Meleagris gallapavo) 41.2 
Domestic chicken (Gallus gallus) 41.5 
Great horned owl (Bubo virginianus) 39.9 
Rock pigeon (Comlumbia livia) 42.2 
California quail (Callipepla californica) 41.3 
Domestic duck (Anas platyrhnchos) 42.1 
Brown-necked raven (Corvus corax ruficollis) 39.9 
Tengmalm’s owl (Aegolius funereus) 39.4 
American kestrel (Falco sparverius) 39.3 
Zebra finch (Poephila guttata) 40.3 
    (Whittow, 1999) 
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avian species is controlled by different mechanisms than is human thermoregulation 
(Whittow, 1999). 
Body Temperature and Protein Glycation. No previously published studies have 
specifically examined the in vivo relationship between temperature and glucose 
concentration and protein glycation for either birds or humans. In regards to the effect of 
temperature on in vitro protein glycation, one published study examining this relationship 
in humans was identified. Urbanowski et al. published results in 1982 from a study 
examining the non-enzymatic glycosylation of human serum albumin (Urbanowski, 
Cohenford, & Dain, 1982). For the temperature specific experiments, purified human 
serum albumin was incubated in vitro for 24 hours at various temperatures (5°C, 25°C, 
35°C, 45°C, and 55°C) with a constant concentration of D-galactose or D-glucose 
(Urbanowski et al., 1982). The results showed that as the incubation temperature 
increased an increase in protein glycation was observed. This increase in protein 
glycation at higher temperatures was observed for both human serum albumin samples 
incubated with D-galactose as well as D-glucose (Urbanowski et al., 1982).  
 The results of this study suggest that increased body temperature will increase 
protein glycation. Preliminary data from several avian species as presented above 
suggests that the opposite relationship may be present in avian species as they have 
higher temperatures than humans along with lower percent glycation, thus there is a 
discrepancy in the literature in regards to this topic. The study conducted by Urbanowski 
et al. (1982) was only conducted using human serum albumin, thus these finding cannot 
be extrapolated to serum albumin from avian species. Additional studies comparing both 
human serum albumin and avian serum albumin are needed to confirm that the 
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relationship between temperature and human serum albumin is consistent in avian serum 
albumin as well. Also, the samples in the Urbanowski et al. (1982) study were only 
incubated for 24 hours prior to analysis for protein glycation. This incubation period was 
constant for all samples; however, a longer incubation period may elucidate time-
dependent effects of temperature on protein glycation. In addition, the temperatures at 
which the samples were incubated did not simulate physiological conditions or avian 
conditions. The incubation temperatures of 35°C and 45°C were the closest to human and 
avian physiological temperatures, however, these do not adequately reflect the 
physiological conditions of either humans or most avian species. An analysis of protein 
glycation at various temperatures within a physiological range in which the albumin 
protein is functional is necessary to confirm this observed relationship. Finally, these 
results were obtained in vitro. The effect of the physiological environment must be 
addressed in future research as it could have a significant impact on the rate of protein 
glycation.  
 As previously mentioned, some foods and food components such as spices, teas, 
and caffeine have been shown to elicit changes in metabolism and impact thermogenesis 
(Westerterp-Plantenga et al., 2006). The resultant increase in body temperature observed 
in humans after consumption of these foods is short-lived and thermoregulation processes 
will act to lower body temperature back to the basal level (Westerterp-Plantenga et al., 
2006). Supplementation of vitamin C has also been shown to significantly raise body 
temperature (C. C. S. Johnston, 1990; C. S. Johnston, 1989). The fact that there are 
identified ways to safely and significantly affect human body temperature suggests that 
there could be the potential for the development of novel therapies to mildly alter body 
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temperature in humans to limit postprandial protein glycation if such a relationship is 
confirmed. In fact, one study has found a decrease in protein glycation among humans 
that took an oral vitamin C supplement (Davie, Gould, & Yudkin, 1992). In this study, 
non-diabetic adults consumed an oral dose of 1000mg ascorbic acid daily for three 
months (Davie et al., 1992). Glycosylated hemoglobin and glycosylated albumin were 
both measured in all participants using affinity chromatography. Both glycosylated 
hemoglobin and glycosylated albumin were significantly decreased after three months of 
ascorbic acid supplementation, from 6.18 ± 0.48% (mean ± SD) to 5.05 ± 0.50% for 
glycosylated hemoglobin and from 1.56 ± 0.24% (mean ± SD) to 1.04 ± 1.01% for 
glycosylated albumin (Davie et al., 1992). There was no control group in this study for 
comparison; this flaw in the study design as well as other limitations of the study (i.e. the 
inclusions of only healthy, non-diabetic adults) limits the impact of the results. 
Nonetheless, the findings are compelling and support a potential link between body 
temperature and protein glycation. No such study has been conducted in avian species. 
Interestingly, several species of birds are able to synthesize ascorbic acid endogenously 
and are not reliant upon dietary sources of this compound (Chaudhuri & Chatterjee, 
1969). Future studies need to investigate whether this observed relationship between 
protein glycation and vitamin C supplementation was indeed mediated through an 
increase in body temperature or if there was another mechanism responsible. 
 Overall, there has been very little investigation into the effect of physiological 
temperature change on protein glycation in either humans or avian species. This 
relationship merits further investigation due to the fact that there is biological plausibility 
to the proposed theory that increased body temperature in avian species is the primary 
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mechanism to explain the decreased protein glycation despite significantly increased 
plasma glucose concentration. Specific, focused studies looking directly at protein 
glycation of human plasma proteins at various physiologic temperatures compared to 
avian plasma proteins are needed to elucidate the exact nature of this relationship. No 
matter the specific results of such studies, the findings will contribute to our 
understanding of avian glucose regulation and transform the understanding of protein 
glycation by elucidating the contributions made by plasma glucose concentration and 
body temperature. 
 Human Relevance of Unraveling the ‘Avian Paradox’. Unraveling the ‘avian 
paradox’ will contribute to the understanding of avian glucose regulation and aid in the 
understanding of the influence of plasma glucose concentration and body temperature on 
protein glycation in birds as well as humans. Traditional therapies to deal with protein 
glycation in humans have focused on the management of side effects or on lowering 
blood glucose levels. Obtaining a full understanding of the ‘avian paradox’ would offer 
an alternative approach by studying what makes proteins susceptible to glycation in the 
first place. Research in this area has the potential to lead to the development of therapies 
to prevent or reverse protein glycation prior to the formation of irreversible AGEs and 
thus avoid their detrimental effects. Therapies of this sort would be of particular interest 
to diabetic humans, as many complications associated with this disease stem from 
increased protein glycation due to prolonged exposure to high blood glucose 
concentrations (Brownlee, 1984). Specifically, investigation into the role of temperature 
and glucose concentration on protein glycation in avian species as compared to humans 
will identify if interspecies differences exist. 
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CHAPTER 3 
MATERIALS AND METHODS 
 Materials. Purified chicken serum albumin (Equitech-Bio, Inc., Kerrville, TX; Cat 
No. CSA62 Lot #CSA62-1254) and human serum albumin (Sigma Aldrich, St. Louis, 
MO; Cat No. A3782 Lot #SLBD7204V) were purchased from commercially available 
sources to be used in the in vitro manipulations. Chicken serum albumin (CSA) has a 
reported purity ≥ 96% and human serum albumin has >99.9% purity. HEPES buffered 
saline solution was prepared in batches of 250 mL by combining 1.963g NaCl (Cat. No. 
S9888, Sigma-Aldrich, St. Louis, MO), 0.112g KCl (Cat. No. P4504, Sigma, St. Louis, 
MO), 0.051g MgCl2 (Cat. No. M2670, Sigma-Aldrich, St. Louis, MO), 0.065g CaCl2 
(Cat. No. C3881, Sigma-Aldrich, St. Louis, MO), and 0.595g NaHEPES (Cat. No. 
H3784, Sigma, St. Louis, MO) in a total volume of 250 mL deionized water. D-glucose 
stock solution (27.78 mM/L) (Cat. No. G8270, Sigma-Aldrich, St. Louis, MO) was 
prepared in deionized water. 
 Human and Chicken Serum Albumin Sample Incubation Protocol. Human and 
chicken serum albumin solutions were prepared with the following glucose 
concentrations: 0 mM, 5.56 mM (normal human), 11.11 mM (normal avian), and 22.22 
mM (Table 5). Human and chicken serum albumins were incubated at various 
temperatures (37.0°C (normal human), 39.8°C (normal avian), and 41.4°C) on separate 
occasions. To prepare the solutions for the incubations, HSA or CSA were added to 10 
mL of the HEPES-buffered saline solution to create a solution containing 0.47 mM 
albumin.  Both solutions were pH adjusted to 7.4 using HCl and/or NaOH as necessary 
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using a ROSS electrode (VWR Symphony pH meter, Radnor, PA) and were then sterile-
filtered using a syringe filter. Glucose was then added at varying concentrations to the  
albumin-HEPES solutions as indicated in Table 5.   
 
 Aliquots (100 µL) of the CSA and HSA-HEPES solutions with varying glucose 
concentrations were then transferred to PCR tubes in triplicate. The schematic of the 
incubations is detailed in Figure 3. All samples were incubated in a thermal cycler 
(MyCycler, Biorad, Hercules, CA) set to run at a constant temperature indefinitely at 
each specified temperature (37.0°C, 39.8°C, or 41.4°C). Aliquots of 2µl were extracted 
from all samples at baseline (day 0), day 3, and day 7 and stored at -80°C until analyses 
(see Appendix A).  
 Measurement of Percent Glycated Albumin by LC-ESI-MS. All aliquots extracted 
were diluted in a 30:1 ratio with 0.1% trifluoroacetic acid (TFA) and analyzed intact by 
liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) (Dr. 
Chad Borges, BioDesign Institute, ASU) on a Dionex Ultimate 3000 HPLC equipped 
with a 1:100 flow splitter connected to a Bruker Maxis 4G quadrupole-time-of-flight (Q-
TOF) mass spectrometer. A trap-and-elute form of LC-MS was carried out in which 15-
µL samples were loaded at 10 µl/min in 80/20 water/acetonitrile containing 0.1% formic  
Table 5. Preparation of the albumin-HEPES solutions with varying glucose 
concentrations  
Final Glucose Concentration Volume of albumin-
HEPES solution 
Volume of 27.78 mM 
glucose stock solution 
0 mM 500 µL  0 µL  
5.56 mM 499 µL  1 µL  
11.11 mM 498 µL  2 µL  
22.22 mM 496 µL  4 µL  
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Figure 3. Schematic of the samples incubated at various temperatures. A: 37.0°C; B: 
39.8°C; C: 41.4°C. 
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acid (loading solvent) onto a Bruker-Michrom protein captrap configured for bi-
directional flow on a 6-port diverter valve. The flow over the captrap was then switched 
to the micropump, set at 2 µL/min, and ramped over 5 minutes from 80% water 
containing 0.1% formic acid (Solvent A) / 20% acetonitrile (Solvent B) to 90% 
acetonitrile and held for 3 min. The captrap eluent was directed to the mass spectrometer 
operating in positive ion, TOF-only mode, acquiring spectra in the m/z range of 300 to 
3000 with a nominal resolving power of ~60,000 m/Δm FWHM.  ESI settings for the 
Agilent G1385A capillary microflow nebulizer ion source were as follows: End plate 
offset -500 V, capillary -3500 V, nebulizer nitrogen 2 bar, dry gas nitrogen 3.0 L/min at 
225 °C.  Data were acquired in profile mode at a digitizer sampling rate of 4 GHz. 
Spectra rate control was by summation at 1 Hz. 
 HSA eluted over a period of about 1 minute; under the above conditions, HSA 
ranged in charge state from +32 to +71.  Raw mass spectra were averaged across this 
timeframe, smoothed 0.0482 Da, baseline subtracted 0.85, charge deconvoluted and 
baseline subtracted 0.85 with Bruker DataAnalysis 4.1 charge deconvolution software to 
a mass range of 1000 Da on either side of any identified peak. 
 CSA eluted over a period of about 0.5 minute; under the above conditions, CSA 
ranged in charge state from +32 to +64.  Raw mass spectra were averaged across this 
timeframe, smoothed 0.0482 Da, baseline subtracted 0.85, charge deconvoluted and 
baseline subtracted 0.85 with Bruker DataAnalysis 4.1 charge deconvolution software to 
a mass range of 1000 Da on either side of any identified peak (see Appendix B). 
 Percent Glycated Albumin Calculation. The mass spectra obtained from the LC-
ESI-MS analysis of each sample were used to calculate percent glycated serum albumin. 
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 For HSA samples, the peak counts corresponding to the peaks for S-cysteinylated 
albumin (~66558 Da), glycated S-cysteinylated albumin (~66720 Da), and doubly 
glycated S-cysteinylated albumin (~66882 Da) obtained from the mass spectra (see 
Appendix C) were used in the following formula to calculate percent glycated albumin: 
Percent Glycated Human Serum Albumin = {[glycated S-cysteinylated albumin + 
2(doubly glycated S-cysteinylated albumin)] / [S-cysteinylated albumin + glycated S-
cysteinylated albumin + doubly glycated S-cysteinylated albumin]} * 100.  
 For CSA samples, the peak counts corresponding to the peaks for native albumin 
(~66874 Da), glycated albumin (~67036 Da), and doubly glycated albumin (~67198 Da) 
obtained from the mass spectra (see Appendix D) were used in the following formula to 
calculate percent glycated albumin: Percent Glycated Chicken Serum Albumin = 
{[glycated albumin + 2(doubly glycated albumin)] / [native albumin + glycated albumin 
+ doubly glycated albumin]} * 100.  
 Slightly different formulae were used for the calculation of percent glycation of 
HSA and CSA. This was due to the fact that CSA does not have a S-cysteinylated form as 
HSA does. The S-cysteinylated albumin form was used for the percent glycation of HSA 
calculation instead of the native albumin form because the intensity of the S-cysteinylated 
peak in the samples tended to be stronger than that of the native peak, thus the S-
cysteinylated peaks gave a more accurate reading. The underlying assumption was made 
that glycation of HSA occurs in equal proportion in native and S-cysteinylated forms, 
which holds true both in theory as well as in unpublished evidence seen to date. 
 Statistical Analyses. Percent glycated albumin was measured on a total of 12 
unique treatment conditions at three distinct time points for both HSA and CSA. All 
!  38 
statistical analyses were performed using SPSS Statistics version 22. All data are 
expressed as mean ± SEM. Data was arcsine transformed by taking the arcsine of the 
decimal value of each data point to achieve normality. Data was normally distributed 
within each day for all albumin type, temperature, glucose concentration group based on 
results of the Shapiro-Wilk test of normality. All data was analyzed using 4-way 
repeated-measures analysis of variance (ANOVA) to examine the change in percent 
glycation of human and chicken serum albumin over time with each treatment and to 
identify significant interactions among all independent variables. Two-way repeated 
measures ANOVA tests were run to explore confirmed interactions and to confirm 
between group variations within specific time points. A Bonferroni procedure was used 
for all post hoc analyses. The sphericity assumption of all repeated measures ANOVA 
tests was met if the Greenhouse-Geisser Epsilon value was greater than or equal to 0.75; 
if the assumption was not met, then the Greenhouse-Geisser correction factor was used to 
adjust the degrees of freedom. A p-value ≤ 0.05 (alpha set to 0.05) was considered 
significant. 
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CHAPTER 4 
RESULTS 
 Main Effects of Temperature, Glucose Concentration, and Albumin Type on 
Percent Glycated Albumin Across Time. The results of the four-way repeated measures 
ANOVA test are summarized below in Table 6. There was not a statistically significant 
difference between Albumin Type (Human Serum Albumin and Chicken Serum 
Albumin) group means (p = 0.095). There was a statistically significant difference in 
temperature group means (p < 0.001); the mean percent glycated albumin for both 
chicken and human serum albumin at all glucose concentrations and on all days is 
significantly higher at 41.4°C than at 37.0°C (p = 0.001) and at 39.8°C (p = 0.038). In 
regards to glucose concentration group means, there was a statistically significant 
difference (p < 0.001). Specifically, the mean percent glycated albumin for both chicken 
and human serum albumin at all temperatures significantly increased as glucose 
concentration increased (p < 0.001 for all comparisons). Also, there was a statistically 
significant difference in means across time (p < 0.001). The mean percent glycated 
albumin for both chicken and human serum albumin at all temperatures and all glucose 
concentrations significantly increased across time points (p < 0.001 for all comparisons). 
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Table 6. Four-Way Repeated Measures ANOVA Summary Table 
Source 
Sum of 
Squares 
(SS) Df 
Mean 
Squares 
(MS) F P-value 
Between Subjects      
Albumin Type 0.006 1.000 0.006 1.901 0.174 
Temperature 0.046 2.000 0.023 7.509 *0.001 
Glucose Concentration 1.835 3.000 0.612 199.338 *<0.001 
Albumin Type x Temperature 0.025 2.000 0.012 4.030 *0.024 
Albumin Type x Glucose 
Concentration 0.294 3.000 0.098 31.972 *<0.001 
Temperature x Glucose 
Concentration 0.125 6.000 0.021 6.764 *<0.001 
Albumin Type x Temperature x 
Glucose Concentration 0.029 6.000 0.005 1.563 0.179 
Error 0.147 48.000 0.003   
Within Subjects      
Time 0.231 1.409 0.164 93.382 *<0.001 
Time x Albumin Type 0.397 1.409 0.282 160.786 *<0.001 
Time x Temperature 0.023 2.818 0.008 4.608 *0.006 
Time x Glucose Concentration 1.294 4.227 0.306 174.583 *<0.001 
Time x Albumin Type x 
Temperature 0.022 2.818 0.008 4.444 *0.008 
Time x Albumin Type x Glucose 
Concentration 0.223 4.227 0.053 30.080 *<0.001 
Time x Temperature x Glucose 
Concentration 0.071 8.455 0.008 4.757 *<0.001 
Time x Albumin Type x 
Temperature x Glucose 
Concentration 0.039 8.455 0.005 2.600 *0.014 
Error 0.119 67.639 0.002     
     Sphericity assumption was not met, thus the Greenhouse-Geisser correction factor 
was used to obtain the values presented for Within Subjects. Albumin Type, Human or 
Chicken Serum Albumin. Temperature, 37°C or 39.8°C or 41.4°C. Glucose 
Concentration, 0mM or 5.56mM or 11.11mM or 22.22mM. Time, Day 0 or Day 3 or 
Day 7. * P ≤ 0.05 
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Interaction Effects of Temperature, Glucose Concentration, and Albumin Type on 
Percent Glycated Albumin across Time. All possible interactions, except for the 
interaction of albumin type x temperature x glucose concentration, were significant based 
on the results of the four-way repeated measures ANOVA test (see Table 6). The 
statistically significant interaction between glucose concentration, temperature, albumin 
type, and time (p = 0.032) indicates that all independent variables interact to affect the 
mean percent glycation of albumin. Two-way repeated measures ANOVA were used to 
characterize these interactions. Figures 4, 5, and 6 directly compare the effect of varying 
glucose concentrations on the percent glycation of HSA and CSA at 37.0°C, 39.8°C, and 
41.4°C, respectively. As shown in the figures, as glucose concentration increased, the 
percent glycation of HSA and CSA increased over time at all temperatures. In addition, 
HSA was glycated to a greater extent in comparison to CSA at the two higher glucose 
concentrations examined for all temperature conditions. 
 The 0 mM glucose concentration did not differentially affect percent glycation of 
HSA and CSA at any temperature examined (p = 0.230 for 37.0°C, p = 0.215 for 39.8°C, 
and p = 0.065 for 41.4°C). Both CSA and HSA decreased in percent glycation over time 
at all temperatures examined at the 0 mM glucose concentration (see Figure 4A, 5A, and 
6A). The percent glycation of HSA and CSA were differentially affected by the 5.56 mM 
glucose concentration at the two highest temperatures examined (p = 0.039 for 39.8°C, 
and p = 0.002 for 41.4°C). At both of these temperatures, CSA decreased in percent 
glycation over time while the percent glycation of HSA remained constant over time (see 
Figure 4B, 5B, and 6B). The 11.11 mM glucose concentration differentially affected 
percent glycation of HSA and CSA at all temperatures (p < 0.001 for 37.0°C, p < 0.001 
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for 39.8°C, and p = 0.001 for 41.4°C). At all temperatures examined the percent glycation 
of CSA remained constant over time, however, the percent glycation of HSA increased 
moderately over time (see Figure 4C, 5C, and 6C). Finally, the 22.22 mM glucose 
concentration also differentially affected percent glycation of HSA and CSA at all 
temperatures (p = 0.001 for 37.0°C, p = 0.004 for 39.8°C, and p = 0.004 for 41.4°C). The 
percent glycation of HSA and CSA both increased over time at all temperatures, 
however, the percent glycation of HSA increased to a greater extent (see Figure 4D, 5D, 
and 6D). 
 Temperature had a differential effect on the percent glycation of HSA and CSA. 
The increase in percent glycation of HSA over time at the 11.11 mM glucose 
concentration and the 22.22 mM glucose concentration was to a significantly greater 
extent at higher temperatures compared to lower temperatures (see Figures 4C, 5C, and 
6C for 11.11 mM glucose and Figures 4D, 5D, and 6D for 22.22 mM glucose). This 
differential effect of temperature seen at the two highest glucose concentrations examined 
was not significant for CSA.  
 
 
 
 
 
 !!
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CHAPTER 5 
DISCUSSION 
 Discussion of Results. Based on the results of the statistical analyses of the data, 
all three null hypotheses are rejected. The first hypothesis (H0 1) stating that the percent 
glycation of CSA will not significantly differ from the percent glycation of HSA when 
exposed to the same temperatures and glucose concentrations over seven days is rejected 
as the percent glycation of CSA significantly differed from the percent glycation of HSA 
under certain conditions. The second hypothesis (H0 2) stating that variations in 
incubation temperatures will not differentially affect the percent glycation of CSA 
compared to the percent glycation of HSA incubated for seven days at the same glucose 
concentrations is rejected as temperature differentially affected the percent glycation of 
HSA compared to the percent glycation of CSA at the two highest glucose concentrations 
examined. Finally, the third hypothesis (H0 3) stating that variations in glucose 
concentrations will not differentially affect the percent glycation of CSA compared to the 
percent glycation of HSA incubated for seven days when the incubation temperature is 
constant is rejected as glucose concentration differentially affected the percent glycation 
of CSA compared to the percent glycation of HSA over time at all temperatures 
examined. 
 The direct comparison of the effect of temperature and glucose concentration on 
the percent glycation of HSA and CSA has not previously been examined. The results of 
this comparative study are unprecedented, thus duplication of this study is warranted in 
order to confirm these findings. Nonetheless, the examination of the effect of temperature 
on the percent glycation of HSA has been examined in one previously conducted study 
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(Urbanowski et al., 1982). The present findings related specifically to HSA are in 
agreement with the one previously conducted study, which found that the percent 
glycation of HSA increased over time as temperature increased (Urbanowski et al., 
1982).  
 The assumption from previous work showing that the susceptibility of albumin to 
glycation does not greatly differ across mammalian species as it does for other plasma 
proteins (i.e. hemoglobin) (Rendell et al., 1985) needs to be reconsidered given the 
results of the current study. New, more precise techniques for the quantification of 
percent glycation of plasma proteins have been developed since the publication of this 
work. The use of these techniques has the potential to more accurately depict the 
differences in glycation between mammals and avian species as well as identify 
previously overlooked interspecies differences in the susceptibility of albumin to 
glycation. 
 The present findings showing a differential exists in the percent glycation of HSA 
and CSA under the same conditions, which is in agreement with previously published 
studies that have shown other plasma proteins (i.e. hemoglobin) are glycated to a 
significantly lesser degree in several avian species despite higher blood glucose 
concentrations (Rendell et al., 1985; Beuchat & Chong, 1998). Fructosamine has been 
used as a clinical measure of protein glycation, similarly to hemoglobin A1C, as it 
measures the number of ketoamine linkages resulting from the glycation of plasma 
proteins (Anguizola, 2013; Beck, 2011). This method is largely a measure of glycated 
albumin since about 90% of ketoamines are formed from the plasma protein albumin, as 
it is the most abundant plasma protein (Anguizola, 2013). While a normal range for 
!  48 
fructosamine is known humans (Beck, 2011), fructosamine levels have not been 
examined in avian species. In fact, only a few researchers have even specifically 
examined the percent glycation of albumin in avian species. The level of glycated 
albumin in several avian species examined by Rendell et al. (1985) was found to be 
higher than levels in humans (Rendell et al., 1985). However, more recent examination of 
the percent glycation of plasma albumin glycation using more precise measurement 
techniques was observed to be significantly lower in budgerigars (parakeets) in 
comparison to human plasma albumin (Holmes et al., 2001). Again, the present findings 
suggest that the improved methods for quantification of percent glycation more 
accurately depict the true level of albumin glycation in avian species. 
 In addition, the findings of this study reinforce our current understanding of 
protein glycation at physiological conditions in both humans and chickens (Brownlee et 
al., 1984; Ulrich & Cerami, 2001). When incubated at the condition most physiologically 
relevant for a human (5.56 mM glucose at 37.0°C), the percent glycation of HSA was at 
equilibrium, as the percent glycation remained constant over time. The percent glycation 
of HSA increased over time at glucose concentrations higher than physiological for 
humans (11.11 mM and 22.22 mM glucose) while the percent glycation of HSA 
decreased over time at glucose concentrations lower than physiological for humans (0.00 
mM glucose). The same was true for the glycation of CSA; however, chickens have 
different normal physiological conditions than humans. When incubated at the condition 
most physiologically relevant for a chicken (11.11 mM glucose and 39.8°C), the percent 
glycation of CSA was at equilibrium, as the percent glycation remained constant over 
time. The percent glycation of CSA increased over time at glucose concentrations higher 
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than physiologically normal for chickens (22.22 mM glucose) while the percent glycation 
of CSA decreased over time at glucose concentrations lower than physiologically normal 
for chickens (0.00 mM glucose and 5.56 mM glucose). 
 The observed decrease in percent glycation from day 0 to day 7 at the glucose 
concentration of 0 mM for both CSA and HSA and at the glucose concentration of 5.56 
mM for CSA demonstrates the reversibility of the Schiff base formation reaction 
(Brownlee et al., 1984; Ulrich & Cerami, 2001). This de-glycation of HSA and CSA 
occurred at a similar rate at all temperatures examined. 
 Degradation of the proteins was observed over time during all incubations. All 
samples were diluted at a 30:1 ratio for the LC-ESI-MS analyses, thus the total count 
obtained from the mass spectrum for each sample is indicative of the quantity of albumin 
in the sample. The average total counts for HSA (S-cysteinylated albumin + glycated s-
cysteinylated albumin + doubly glycated s-cysteinylated albumin) was 68738 on Day 0, 
53797 on Day 3, and 30392 on Day 7. The average total counts for CSA (native albumin 
+ glycated albumin + doubly glycated albumin) was 85295 on Day 0, 56571 on Day 3, 
and 28888 on Day 7. This decrease in total albumin is not due to loss to the glycated 
albumin pool as the average total counts for HSA and CSA include the glycated albumin 
pool. Based on the average total counts obtained from the mass spectrum of each sample, 
CSA degraded at a faster rate than HSA. This difference in degradation of HSA and CSA 
has been reported previoulsy in published literature (Rendell et al., 1985). Regardless, the 
percent glycation is a reflection of the amount of glycated albumin as a ratio of the total 
albumin present in each sample at each time point. In regard to the disparity in elution 
time observed between CSA and HSA, this likely has to due with differences in the 
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relative affinity of the different albumin molecules to the hydrophobic protein captrap 
that was used; however, this is merely speculation and further research would be 
necessary to address this difference. 
 Unlike humans, temperature was not found to have a significant effect on the 
percent glycation of CSA. This finding indicates that the reactant-favored chemical 
environment (i.e. higher body temperature of avian species in comparison to humans) is 
not the mechanism by which birds resist protein glycation. In fact, lack of effect of 
temperature on the percent glycation of CSA adds to the complexity of the ‘avian 
paradox’ as it indicates that birds also resist the increase in protein glycation at higher 
temperatures than those seen in humans. 
 Strengths and Limitations. There were several strengths of this study. The in vitro 
manipulations were conducted in a highly controlled environment and thus equalized the 
background matrix between the two types of albumin. This allowed for the direct 
comparison of the purified human and chicken albumin molecules at a range of 
physiologically relevant temperatures and glucose concentrations. The commercially 
purchased CSA and HSA are pooled samples from numerous individual animals, thus 
individual variation in the protein molecule is accounted for and a small sample size 
(n=3) is sufficient. Both the HSA and CSA were highly purified assuring that impurities 
were not responsible for influencing the data or contaminating the results. In addition, the 
use of LC-ESI-MS as the method for the quantification and calculation of percent 
glycation of both HSA and CSA is both precise and reliable. The ability to differentiate 
between singly and doubly glycated albumin is unique to this method and strengthens the 
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accuracy of the data as compared to prior studies that only measured singly glycated 
albumin.  
 Despite the strengths associated with an in vitro experiment, there are inherent 
limitations as well. The in vitro environment does not adequately simulate the in vivo 
conditions. Thus, there could be other factors that play a role in the in vivo setting that are 
not accounted for in an in vitro study. For example, there could be other serum factors 
that impact protein glycation. In addition, the results of this study are not generalizable to 
the whole animal (either human or chicken) nor are they generalizable to any species not 
included in this study. Further research is needed to determine if all avian albumin is 
glycated similarly to chicken albumin. Lastly, there was some degree of oxidation of the 
CSA and HSA molecules that occurred over time during the incubations, particularly the 
day 7 samples of both HSA and CSA at the 22.22 mM glucose concentration at all 
temperatures. Although oxidation increased the variability of the percent glycation data, 
it was not sufficient to affect the statistical conclusions. Increasing the total volume of the 
incubation and/or adding 1 mM EDTA to the samples prior to incubation to minimize 
transition metal redox cycling and generation of reactive oxygen species are two ways 
that this oxidation can be prevented in future studies. The addition of EDTA was not 
done in this study in order to simulate physiological conditions as closely as possible.  
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CHAPTER 6 
CONCLUSIONS AND APPLICATIONS 
 Further research is needed to fully unravel the ‘avian paradox’. This study 
revealed that temperature is not the mechanism by which birds protect against protein 
glycation. Specifically, temperature did not impact percent glycation of CSA, but 
temperature did impact percent glycation of HSA at the highest glucose concentrations. It 
was also shown that as glucose concentration increased, the percent glycation of both 
HSA and CSA increased. HSA was glycated to a greater extent when compared to CSA 
in the presence of high glucose concentrations. 
 The results of this study suggest there is an inherent difference between the 
purified forms of human and chicken albumin that contributes to the differential 
glycation. One possible explanation for this inherent difference is a structural variation in 
the chicken and human albumin proteins. The chicken albumin protein may be folded in 
such a way that the amino acid residues (i.e. lysine) that glucose binds to are protected or 
shielded, thus decreasing the susceptibility of the protein to glycation. Future 
investigations should focus on determining the tertiary structure of avian albumin 
molecules in order to compare to that of human albumin molecules. Further, this study 
does not sufficiently rule out the possible role of serum factors or other factors affecting 
plasma conditions (ie. pH) as contributing to the paradoxical difference in protein 
glycation seen between birds and humans. Therefore, additional research is recommended 
to determine the complexity of the mechanism and determine if inherent protein 
difference is the only factor at play or if there are several factors interacting to result in 
protection from protein glycation.  
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 There are significant human applications of this research. Specifically, the 
findings of this study reinforce the importance for diabetic humans to maintain normal 
blood glucose concentrations, especially during illness/fever, in order to limit protein 
glycation. Future related work could result in additional human applications. For 
instance, the identification of the specific mechanism of protection from protein glycation 
has the potential to lead to the development of novel therapies to help individuals with 
diabetes prevent protein glycation and therefore limit the production of AGEs. The 
prevention of AGE formation altogether would drastically reduce the number of diabetic 
individuals developing severe diabetic complications. If a tertiary structure difference 
between chicken and human albumin proves true, such therapies could be in the form of a 
drug or a natural compound found in the diet that acts by blocking amino acid residues to 
prevent the initial glycation from occurring in humans. In addition, since the possibility 
of serum factors or other serum conditions as contributing factors has not been ruled out 
by the present study, then another potential therapy would be a mimetic of specific serum 
factors found in chickens administered to humans. A natural therapy, such an element 
found in the diet, might be preferable to a synthetic therapy as it would ease medical 
expenses in a population that already spends a substantial amount on healthcare annually 
(i.e. diabetics). If additional investigations ultimately reveal that the innate difference 
between chicken and human purified albumin cannot be overcome by the development of 
novel therapies, at the very least the body of scientific knowledge will have grown and 
further efforts can be shifted in another promising direction.  
 All in all, the differential effects of temperature and glucose concentration on the 
glycation of CSA and HSA suggest an inherent difference in these proteins, which is a 
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significant contributing factor in the mechanism by which birds are protected from 
protein glycation. The nature of this difference is unknown and the results of this study 
strongly support the need for further research in order to unravel this mechanism. 
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APPENDIX A  
PROTOCOL FOR HSA/CSA SAMPLE INCUBATION PREPARATION 
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Methods 
Materials: 
 Purified Human Serum Albumin 
 Purified Chicken Serum Albumin 
 HEPES Buffered saline: 
 134.4 mM NaCl 
 6 mM KCl 
 1 mM MgCl2 
 1.8 mM CaCl2 
 10 mM NaHEPES 
D-glucose 
DI water 
 
Sample Preparation: 
1. Prepare 1 mL of a 500mg/mL glucose stock solution in DI water (final 
concentration 0.5mg/uL). 
2. Make 250mL of HEPES buffer (fill to volume and do not adjust pH at this point) 
3. Make 10mL of 8.4mg/mL (84 mg in 10 mL) human serum albumin (HSA) or 
chicken serum albumin (CSA) dissolved in this high pH HEPES (fill to volume). 
4. Adjust pH to 7.4 using the ROSS electrode using HCl and/or NaOH as necessary. 
5. Sterile filter solution. 
6. Make one 1-mL solutions for each of the samples 1-8 below. Take out three final 
150uL aliquots for incubation in the Thermocycler. 
  Sample 1: 0mM glucose HSA  
   (1000uL HEPES with HSA) 
  Sample 2: 5.56mM glucose HSA  
   (2uL 500mg/mL glucose + 998 HEPES with HSA) 
  Sample 3: 11.11mM glucose HSA  
   (4uL 500mg/mL glucose + 996 HEPES with HSA) 
  Sample 4: 22.22mM glucose HSA  
   (8uL 500mg/mL glucose + 992 HEPES with HSA) 
  Sample 5: 0mM glucose CSA  
   (1000uL HEPES with CSA) 
  Sample 6: 5.56mM glucose CSA  
   (2uL 500mg/mL glucose + 998 HEPES with CSA) 
  Sample 7: 11.11mM glucose CSA  
   (4uL 500mg/mL glucose + 996 HEPES with CSA) 
  Sample 8: 22.22mM glucose CSA  
   (8uL 500mg/mL glucose + 992 HEPES with CSA) 
 
7. Incubate at 37.0, 39.8, or 41.4°C for seven days, taking a 2 uL aliquot off each 
sample at baseline, end of day 3, and end of day 7.  
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APPENDIX B  
PROTOCOL FOR LC-ESI-MS ANALYSIS OF HSA/CSA SAMPLES FOR PERCENT 
GLYCATION 
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Machine Preparation: 
1. Turn MS from ‘stand-by’ mode to ‘operate’ mode 
2. Change loading flow from 3µl/min to 10µl/min and change micro flow from 
0.105µl/min to 3µl/min 
3. Screw in the connection between the LC and MS 
4. Clean source using methanol and water 
5. Clean needle using methanol and water 
Sample Preparation: 
8. Prepare 5ml 0.1% TFA by combining 4.95ml distilled H2O with 50µl 10% TFA 
stock solution. 
9. Remove sample from -80°C and place on ice. 
10. Prepare 30:1 dilution of HSA/CSA sample by combining 15µl 0.1% TFA with 
0.5µl sample. Vortex diluted sample. 
11. Load 15µl of the diluted sample into one well of the 96-well plate. 
12. Load 40µl of 0.1% TFA into a separate well of the 96-well plate. 
13. Load 96-well plate onto the plate-holder of the LC-MS. 
14. Acquisition the two wells as follows: 
a. Sample well- 
i. Injections: 1 
ii. Amount: 5.000µl  
iii. LC Method Part: crb_protein trap and ramp 
iv. Autosampler Method Part: Standard 
v. MS Acquisition Method Part: 150126 protein 
b. Solvent well- 
i. Injections: 1 
ii. Amount: 10.000µl  
iii. LC Method Part: crb_protein trap and ramp 
iv. Autosampler Method Part: Standard 
v. MS Acquisition Method Part: 150126 protein 
Spectra Analysis: 
1. Open Spectra in Compass DataAnalysis 
2. Average raw spectra across the approximate 1 min (HSA) or 0.5 min (CSA) 
timeframe of sample elution 
3. Copy to compound spectra 
4. Smooth spectra (0.0492 Da) 
5. Baseline subtraction (0.85) 
6. Charge Deconvolution 
7. Baseline Subtraction (0.85) 
8. Record the mass (m/z) and counts for the relevant peaks for HSA samples (native 
albumin, S-cysteinylated albumin, glycated albumin, s-cysteinylated + glycated 
albumin, and s-cysteinylated + doubly glycated albumin) or for CSA samples 
(native albumin, glycated albumin, doubly glycated albumin) 
9. Calculate Percent Glycated Albumin for each spectrum using the appropriate 
counts. 
10. Save spectra
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 APPENDIX C  
EXAMPLE OF HUMAN SERUM ALBUMIN MASS SPECTRUM FROM A SAMPLE 
INCUBATED AT 39.8°C AT 11.11mM GLUCOSE EXTRACTED ON DAY 3  
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APPENDIX D  
EXAMPLE OF CHICKEN SERUM ALBUMIN MASS SPECTRUM FROM A 
SAMPLE INCUBATED AT 39.8°C AT 11.11mM GLUCOSE EXTRACTED ON DAY 
3 
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